| pubmed-article:10871325 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10871325 | lifeskim:mentions | umls-concept:C0020663 | lld:lifeskim |
| pubmed-article:10871325 | lifeskim:mentions | umls-concept:C0036751 | lld:lifeskim |
| pubmed-article:10871325 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:10871325 | lifeskim:mentions | umls-concept:C0178702 | lld:lifeskim |
| pubmed-article:10871325 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:10871325 | lifeskim:mentions | umls-concept:C0290799 | lld:lifeskim |
| pubmed-article:10871325 | lifeskim:mentions | umls-concept:C1292733 | lld:lifeskim |
| pubmed-article:10871325 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10871325 | pubmed:dateCreated | 2000-7-24 | lld:pubmed |
| pubmed-article:10871325 | pubmed:abstractText | Treatment with selective serotonin reuptake inhibitors induces a desensitization of hypothalamic postsynaptic 5-hydroxytryptamine (5-HT)(1A) receptors in humans and rats. This study investigated whether fluoxetine-induced desensitization is due to overactivation of postsynaptic 5-HT(1A) receptors; whether blockade of somatodendritic 5-HT(1A) autoreceptors accelerates this desensitization; and whether desensitization is associated with a reduction of Gz proteins, which couple to 5-HT(1A) receptors. WAY-100635 was tested at low doses (0.03-0.3 mg/kg), which antagonize somatodendritic 5-HT(1A) autoreceptors in the raphe nuclei, and at a higher dose (1 mg/kg), which completely blocks postsynaptic 5-HT(1A) receptors. Plasma levels of oxytocin and adrenal corticotrophic hormone (corticotropin) were measured as peripheral indicators of hypothalamic 5-HT(1A) receptor function. Daily injections of fluoxetine (10 mg/kg/day i.p.) for 2 days did not desensitize 5-HT(1A) receptors but three daily injections of fluoxetine produced a partial desensitization of the hormone responses to (+/-)-8-hydroxy-2-dipropylaminoetetralin (50 microg/kg s.c.). WAY-100635 (0.03-0.3 mg/kg) did not accelerate or potentiate the fluoxetine-induced desensitization of 5-HT(1A) receptors. However, WAY-100635 at a dose that completely blocks postsynaptic 5-HT(1A) receptors (1.0 mg/kg) completely prevented the fluoxetine-induced desensitization of 5-HT(1A) receptors. These data demonstrate that at least 3 days of fluoxetine exposure is required to produce a homologous desensitization of hypothalamic 5-HT(1A) receptors. Although previous studies indicate that injections of fluoxetine for 14 days produce a reduction of Gz protein levels in the hypothalamus, the levels of Gz proteins were not affected by either fluoxetine or WAY-100635. Alternative mechanisms mediating the initial stages of 5-HT(1A) receptor desensitization could involve post-translational modifications in the 5-HT(1A) receptor-Gz protein-signaling cascade. | lld:pubmed |
| pubmed-article:10871325 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10871325 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10871325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10871325 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10871325 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:10871325 | pubmed:issn | 0022-3565 | lld:pubmed |
| pubmed-article:10871325 | pubmed:author | pubmed-author:BattagliaGG | lld:pubmed |
| pubmed-article:10871325 | pubmed:author | pubmed-author:GarciaFF | lld:pubmed |
| pubmed-article:10871325 | pubmed:author | pubmed-author:Van de KarL... | lld:pubmed |
| pubmed-article:10871325 | pubmed:author | pubmed-author:MumaN ANA | lld:pubmed |
| pubmed-article:10871325 | pubmed:author | pubmed-author:SerresFF | lld:pubmed |
| pubmed-article:10871325 | pubmed:author | pubmed-author:RaapD KDK | lld:pubmed |
| pubmed-article:10871325 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10871325 | pubmed:volume | 294 | lld:pubmed |
| pubmed-article:10871325 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10871325 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10871325 | pubmed:pagination | 296-301 | lld:pubmed |
| pubmed-article:10871325 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:meshHeading | pubmed-meshheading:10871325... | lld:pubmed |
| pubmed-article:10871325 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10871325 | pubmed:articleTitle | Coadministration of 5-hydroxytryptamine(1A) antagonist WAY-100635 prevents fluoxetine-induced desensitization of postsynaptic 5-hydroxytryptamine(1A) receptors in hypothalamus. | lld:pubmed |
| pubmed-article:10871325 | pubmed:affiliation | Loyola University of Chicago, Stritch School of Medicine, Department of Pharmacology, Maywood, Illinois 60153, USA. | lld:pubmed |
| pubmed-article:10871325 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10871325 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:10871325 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10871325 | lld:pubmed |
